Kamada Expands Plasma Collection Operations
In an exciting development for Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), the company has announced the opening of a new plasma collection center in San Antonio, Texas. This state-of-the-art facility aims to significantly enhance the company’s plasma collection operations by increasing their capacities and providing a reliable source of specialty plasma.
New Plasma Collection Center Details
The newly established center spans over 11,100 square feet and plans to maintain approximately 50 donor beds, potentially gathering around 50,000 liters of plasma on an annual basis. This ambitious undertaking indicates Kamada's commitment to bolstering its operations and supporting the increasing demand for hyper-immune plasma.
Focus on Specialty Plasma
The San Antonio center will focus on collecting various types of plasma, including normal source plasma and specialty plasma types such as Anti-Rabies and Anti-D. This strategic decision is designed not only to fulfill Kamada's internal needs but also to provide raw materials to third-party entities, thereby enhancing overall revenue streams.
Impact on Business Growth
According to projections, the new center is expected to contribute between $8 million and $10 million to the company’s annual revenues from the sale of normal source plasma, assuming it operates at full capacity. Such financial forecasts are essential for the company's future planning and resource allocation.
Strategic Growth Initiatives
Kamada's decision to expand its facilities aligns with their long-term growth strategy, which encompasses organic and strategic growth avenues. By investing in plasma collection, they aim to enhance their product offering in specialty plasma-derived therapies, catering to the needs of patients with rare conditions.
Future Plans and Regulatory Approvals
The company has set its sights on regulatory approvals for the new center, planning to submit the necessary applications to the U.S. FDA and the European Medicines Agency later in the year. Kamada anticipates receiving approvals from these agencies within 9-12 months, which is a crucial milestone in their operational roadmap.
About Kamada and Its Market Position
Kamada Ltd. is a global biopharmaceutical company known for its innovative approach to treating rare and serious medical conditions. The company's portfolio includes several FDA-approved specialty plasma-derived therapies. As they expand their operations in the U.S., the integration of new facilities like the one in San Antonio is vital for maintaining their competitive edge.
Frequently Asked Questions
What is the purpose of the new plasma collection center in San Antonio?
The San Antonio center aims to enhance Kamada's capacity to collect specialty plasma, support the growing need for hyper-immune plasma, and increase revenue through plasma sales.
What types of plasma will be collected at the new center?
The center will collect normal source plasma as well as specialty plasma types such as Anti-Rabies and Anti-D.
How much revenue is the new center expected to generate?
The new plasma collection center is estimated to contribute between $8 million and $10 million annually when operating at full capacity.
What is Kamada’s growth strategy?
Kamada's growth strategy involves organic growth through commercial activities, expanding plasma collection operations, and securing new business development opportunities.
When does Kamada plan to seek regulatory approvals for the new center?
Kamada intends to submit its approval applications to the U.S. FDA and the European Medicines Agency in the second half of the year.
